profit from every $100 of sales.
$0$100
Odyssey Therapeutics
$20.10-4.24% today
+22.4% since May 8, 26
1-year low $15.561-year high $28.76
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Odyssey Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $2.98 million in 2025, with -$149 million of profit last year.
SalesProfit
Odyssey Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Odyssey Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Odyssey Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 4 | 3 | |
| – | – | – | – | |
| -123 | -133 | -135 | -161 | |
| -121 | -120 | -124 | -145 | |
| -125 | -126 | -129 | -149 | |
| -4.52 | -1.32 | -4.73 | – | |
| – | – | – | – | |
| – | -12,867.8% | -3,023.8% | -5,415.2% | |
| – | -12,144.5% | -2,891.8% | -4,994.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 317 | 287 | 197 | 270 |
| Cash | 241 | 53 | 59 | 42 |
| Total debt | 42 | 34 | 31 | 27 |
| Total liabilities | 462 | 549 | 580 | 758 |
| -145 | -263 | -383 | -488 | |
| 28 | 99 | 28 | – | |
| – | – | – | – | |
| 86.2% | 47.9% | 33.8% | 30.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -100 | -113 | -117 | -129 | |
| 13 | 5 | 1 | 1 | |
| -113 | -118 | -118 | -131 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 6 | 9 | 14 |
Valuation
- –
- –
- –
- –
- 324.7×
- –
- –
- -13.5%
- -15.4%
- –
Profitability
- –
- -5,415.2%
- -4,994.9%
- –
- –
- –
- –
- –
- –
- –
Growth
- +69.4%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 8%of 870
Bottom 7%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Odyssey Therapeutics
Is Odyssey Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Odyssey Therapeutics AI analysis
What does Odyssey Therapeutics do?
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. It is in Biotechnology.
Does Odyssey Therapeutics pay a dividend?
No. Odyssey Therapeutics does not pay a dividend at the moment.
Is Odyssey Therapeutics stock halal?
Yes. Odyssey Therapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
Who are Odyssey Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Odyssey Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.